A workforce that knows its own genetic risk is a new kind of workforce, and most companies have not planned for it.
Cheaper sequencing and broader AI detection mean more of your people learn their own inherited risk every year, often through screening the enterprise may soon sponsor. Between one in twenty and one in eight already have a serious variant. In six weeks, you build the position, the systems, and the manager playbook to meet it on your terms.
Genetic testing has reached scale, which puts it inside your workforce.
Your employees are the ones being tested, and most find out on their own, through a physician, a family diagnosis, or a kit they bought. Between 5 and 13 percent have one of these variants, and the share keeps rising as research ties more genes to disease and each test screens for more of them. The reason is simple: a test that was once rare and costly is now routine and inexpensive.
How many of your people likely have a serious inherited risk?
Enter your numbers; the estimate updates as you go. It is the starting point for the financial picture.
Prevalence: 1 in 20 cancer-predisposition (All of Us, n=414,830, JAMA 2025); up to 1 in 8 including cardiac (Mayo, Genetics in Medicine 2026). Workforce uses all employees; plan uses enrolled plus dependents at the same rate. Spouses do not inherit an employee's variant. A directional planning estimate, not actuarial, medical, or legal advice.
This is established science, and employers are already moving
"I believe that reading our blueprints, cataloguing our own instruction book, will be judged by history as more significant than even splitting the atom or going to the moon."
Francis Collins, the geneticist who led the Human Genome Project and directed the National Institutes of Health for twelve years. Academy of Achievement, 1998.
Four things you get ahead of
The shift shows up in several places at once: at the top, in the systems, on the front line, and in the financial picture. The engagement gets you ahead of all four.
The company's position
Decide, on your own timeline, what the company will and will not do with what its people come to know about themselves. This is the stance the rest of the work builds on.
The systems
Privacy handling, benefits design, and internal communication, designed in advance so they work smoothly when they are needed.
The managers and the human reality
A simple protocol for the moment an employee shares something, including the privacy lines to respect and a clear place to send people for support, so anyone who receives hard news has somewhere to turn.
The financial picture
A directional model of the cost trajectory and the main areas of exposure, built from public benchmarks and your own numbers, so finance has a starting framework rather than a guess.
Three gaps no one yet owns
The knowledge is already arriving
Affordable testing is now widely available, and employees are learning their results through many channels outside the company. The number affected continues to grow, and at most companies no one yet owns the response.
Legal compliance still leaves gaps
Federal law, the Genetic Information Nondiscrimination Act, known as GINA, limits how employers and health plans use genetic information. It does not extend to life, disability, or long-term-care insurance, and its protections fade once a condition develops. A company can follow the law fully and still leave employees exposed where it matters most.
Managers are the first point of contact
An employee may share a result, or simply show strain, and a manager is often the first person there. Most managers have had no guidance on what they may ask, what they may not, and how to help.
What a result means for the person who receives it
For the employee, a result is not just data. What it means varies widely, from a finding of unknown significance that may change nothing, to a manageable cancer risk with clear steps to take, to a result like Huntington's that is predictive and life-altering. The same program can deliver any of these, which is why a thoughtful, human response matters.
A cancer-predisposition variant
Surveillance, decisions about their own body, conversations with family. Heavy, but with concrete steps to take and a path to act on.
A result like Huntington's
A predictive, untreatable diagnosis with little to act on medically. One of the hardest things a person can learn, and it can surface at work.
Often a manager is the first person an employee tells. With modest preparation, that manager can respond with genuine care and direct the person to real support. It is a small thing to put in place, and this work puts it in place.
From unprepared to ready
Unprepared
- –Employees learning their results with no company position in place
- –Managers without guidance for the conversation
- –Privacy and cost questions without a clear owner
- –A response that begins only after an issue surfaces
Ahead of it
- +A clear company position, set early and on your terms
- +Managers prepared to respond with care
- +Privacy, benefits, and communications designed in advance
- +A directional financial picture, modeled rather than guessed
Six weeks, one to one
Each week produces one artifact that builds toward the final readout. About four hours of your time across the whole engagement.
The exposure, quantified
Model your real population against verified prevalence and map where it surfaces across cost, legal, and culture.
The legal and privacy map
Where genetic information creates exposure across GINA, ADA, state law, and your vendor data flows, turned into the questions your counsel can answer.
The manager playbook
What a manager can know, cannot know, and does in the moment, including the mental-health range and how to route to support with care.
The financial picture
A directional model of plan-cost direction, the protection gap, and retention considerations, drawn from public benchmarks and your numbers.
The company's position
Synthesize the work into the stance, the systems to build, and the ninety-day first moves.
Ready to lead it
Pressure-test the position against the hardest questions, from the skeptic to the General Counsel to finance, and the readout that ratifies it.
Three things that reduce your risk
The First-Look Brief
Your exposure number in writing, with the assumptions behind it and the sources, before you commit a dollar.
The Hard-Questions Pack
Sourced answers to the questions your exec team, your counsel, and your board are likely to raise, each number cited by study, date, and sample size.
The First-Move Guide
Every finding arrives with a recommended first step attached, so you always have somewhere to go from here.
A strategy line, not a benefits one
Lauren Berkowitz
Lauren Berkowitz's work proceeds from one premise: genomics is the next platform shift after digital and AI. She holds that view from having been inside the prior two shifts before they were named.
She began in media at Sony's first digital pivot, where her legal background put her at the table for the early Apple, Amazon, and Google deals. She built her AI experience at IBM under the CTO and as Chief of Staff to the VP of Applied AI at Bridgewater. Most recently she led workforce strategy and organizational intelligence at Western Digital, a 55,000-person global enterprise, and earlier was Chief of Staff to a biotech CEO.
She now writes and builds at the intersection of genomics, AI, and workforce transformation, publishing as Ctrl Alt Human and developing a structured intelligence layer mapping the ecosystem around pathogenic genetic variants. She holds a JD and an MBA.
Straight answers
How do I justify this on my budget?
Two ways. It is a small, fixed cost set against a real area of exposure, and you receive a pre-written internal business case you can forward to finance as is. It also sits inside your own discretionary authority, so it does not require a new budget line.
I have capacity for nothing right now.
Total time on your side is about four hours across six weeks. One data pull, no session over an hour, scheduled around enrollment and comp. You are never the bottleneck in your own project.
Will this work for my company, not a case study?
You find out before you pay. The First-Look Brief reads your actual exposure from your real figures, on your headcount, your uptake, your regulatory footprint.
You are one person, not a firm.
Every figure is sourced by study, date, and sample size, and we rehearse the hard questions first. If a director flags monoallelic MUTYH in the 1 in 20, you will have the answer ready: strip it and you are still near 1 in 25, with the citation.
I already pay a consultant and counsel.
They each own one corner. Whether a workforce that increasingly knows its own risk is an asset or a liability lives in the gap between benefits, law, and people strategy, where none of them sits. This engagement stands in that gap and answers it.
The shift is already moving through your workforce. The only question is whether you meet it early.
A free thirty-minute working session, not a pitch. We size your real exposure live, and you leave with the number whether or not we go further. Five founding partners; when they fill, the next start date moves to the following quarter.